Solana Company (HSDT) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
30 Mar, 2026Executive summary
Completed a transformative year, expanding from a passive holding structure to a multifaceted platform with capital markets, asset management, and marketing/partnership activities.
Achieved $5.2 million in Q4 2025 revenue, up from $0.2 million year-over-year, driven by staking rewards.
Closed a $500+ million PIPE transaction in September 2025, marking a new strategic phase.
Reported Q4 net income of $325.6 million, reversing a net loss of $3.9 million in the prior-year quarter, due to a significant gain from derivative liability revaluation.
Expanded business through digital asset treasury, share repurchases, and strategic partnerships.
Financial highlights
Q4 2025 revenue was $5.2 million, with $5.1 million from staking; full year 2025 revenue was $6 million, up from $0.5 million in 2024.
Q4 2025 operating expenses were $206.1 million, including $178.3 million in unrealized losses on digital assets.
Q4 2025 net income was $325.6 million, driven by a $526.3 million gain from derivative liability revaluation; prior year Q4 net loss was $3.9 million.
Full year 2025 net loss was $40.9 million, compared to $11.7 million in 2024.
At year-end, held $7.3 million in cash and $293.7 million in digital assets.
Outlook and guidance
Plans to activate Pacific Backbone nodes in Asia-Pacific, optimize performance, and launch liquidity-related products within 12–18 months.
Continues to focus on long-term SOL accumulation and enhancing SOL per share metrics.
Evaluating capital formation alternatives, including convertible debt, warrant-linked structures, and strategic M&A.
Anticipates further yield enhancement from the Anchorage/Kamino partnership and expects institutional DeFi participation to grow as regulatory clarity improves.
Management remains committed to sustainable growth despite adverse crypto market and macroeconomic headwinds.
Latest events from Solana Company
- First third-party reimbursement and Medicare rates expected to drive late-2024 revenue growth.HSDT
Q2 20241 Feb 2026 - CMS pricing delays hinder access and commercialization, prompting strategic review and regulatory focus.HSDT
Status Update13 Jan 2026 - 6.2 million shares registered for resale after warrant exercises; no proceeds to the company.HSDT
Registration Filing16 Dec 2025 - Registering 6.2M shares for resale after $3.7M in warrant exercises, amid Nasdaq compliance risks.HSDT
Registration Filing16 Dec 2025 - Annual meeting seeks approval for director elections, warrant issuance, and a reverse stock split.HSDT
Proxy Filing2 Dec 2025 - Shareholders will vote on director election, warrant issuances, and expanding the equity plan.HSDT
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, auditor, warrant shares, and reverse stock split for Nasdaq compliance.HSDT
Proxy Filing2 Dec 2025 - Shareholders to vote on director election, warrant issuances, and equity plan amendment.HSDT
Proxy Filing2 Dec 2025 - Shareholders to vote on reverse split, share increase, and financing to maintain Nasdaq listing.HSDT
Proxy Filing2 Dec 2025